Plaquenil
In brief
- Plaquenil (hydroxychloroquine) is supplied via pharmacies and prescription services in Australia and worldwide; it is legally a prescription-only (Rx) medicine, though some pharmacies or online suppliers may at times dispense it without asking for a prescription.
- Plaquenil is used for malaria treatment and prophylaxis, rheumatoid arthritis, systemic and discoid lupus (and some juvenile arthritides). Mechanism: an aminoquinoline that has antimalarial activity (interferes with parasite processes) and immunomodulatory effects (raises lysosomal pH, alters antigen presentation and toll‑like receptor signalling).
- Usual dosages: malaria prophylaxis 400 mg once weekly; malaria treatment typically 800 mg initial then 400 mg at 6, 24 and 48 hours; for RA/SLE 200–400 mg daily (max ~400 mg/day in adults); paediatric dosing is weight-based (e.g. 3–7 mg/kg/day, max 400 mg).
- Administration is oral tablets (most commonly 200 mg film‑coated tablets, taken whole or as scored tablets as instructed).
- Onset: varies by indication — antimalarial protection typically established after 1–2 weeks of prophylaxis, symptomatic relief in autoimmune disease may take 1–2 months, and antimalarial effects on parasites begin within hours with clinical improvement often within 24–48 hours of treatment.
- Duration of action: hydroxychloroquine has a long tissue half‑life (weeks); prophylaxis is given weekly and autoimmune therapy is continued long‑term as needed — drug levels and effects can persist for weeks after stopping.
- Avoid or limit alcohol while taking plaquenil as alcohol can worsen gastrointestinal side effects and may increase liver risk; discuss alcohol use with your prescriber.
- The most common side effect is gastrointestinal upset, particularly nausea; other common effects include headache, dizziness, skin rash and, with long‑term use, risk of retinal toxicity.
- Would you like to try plaquenil without a prescription?
Basic Plaquenil Information
- INN (International Nonproprietary Name): Hydroxychloroquine
- Brand Names Available In Australia: Plaquenil; generics labelled “Hydroxychloroquine Sulfate” are widely available
- ATC Code: P01BA02
- Forms & Dosages: Film-coated tablet 200 mg (common blister packs 30 or 60); 100 mg tablets are rare and less common
- Manufacturers In Australia: Sanofi supplies Plaquenil internationally; generics supplied globally by manufacturers such as Ipca, Zydus Cadila, Cipla and Apotex
- Registration Status In Australia: Prescription (Rx) only; TGA-regulated for listed indications
- OTC / Rx Classification: Prescription-only (S4) medicine
Critical Warnings & Restrictions
Plaquenil (hydroxychloroquine) is a prescription-only medicine in Australia and must be used under medical supervision.
Severe but rare risks include retinal toxicity that can cause irreversible vision loss, cardiac arrhythmia with QT prolongation, severe hypoglycaemia, and potentially fatal overdose in children.
Baseline screening and ongoing monitoring are mandatory for patient safety.
Arrange an ophthalmology baseline within 12 months of starting treatment.
High‑risk patients should have ophthalmic review every 6–12 months while on treatment.
Obtain an ECG before or during treatment if there are cardiac risk factors or concurrent QT‑prolonging drugs.
Do not prescribe Plaquenil without checking for hypersensitivity to 4‑aminoquinolines and prior retinal disease.
High-Risk Groups (Elderly, Pregnancy, Chronic Illness)
Elderly patients require specialist review and closer ophthalmic and cardiac surveillance.
Pre‑existing retinal disease, cardiac conduction disorders, severe liver or kidney impairment, and G6PD deficiency need specialist assessment and dose adjustment or alternative therapy.
Pregnant or breastfeeding women require specialist review and a clear risk‑benefit discussion with documented rationale.
Avoid Plaquenil if known hypersensitivity to hydroxychloroquine or related compounds exists.
Use this checklist before starting Plaquenil:
- Baseline ophthalmology referral and report within 12 months.
- ECG if cardiac history, electrolyte imbalance, or concurrent QT drugs.
- Baseline liver and kidney function tests.
- Pregnancy test where relevant and counselling for pregnancy planning.
Interaction With Activities (Driving, Workplace Safety Under Australian Law)
Hydroxychloroquine can cause dizziness and blurred vision, especially when starting therapy.
Advise patients not to drive or operate heavy machinery until they know how the medicine affects them.
Australian workplace safety obligations require reporting if a worker’s medication impairs performance in safety‑critical roles.
Q&A — Can I Drive After Taking It In Australia?
- Short answer: Not until you know how it affects you.
- If you experience dizziness, blurred vision, or sedation, stop driving immediately.
- Notify your prescriber and, where relevant, your employer or insurer.
- Seek urgent review if vision changes are sudden or severe.
Usage Basics
INN, Brand Names Available In Australia
The International Nonproprietary Name (INN) is hydroxychloroquine.
Plaquenil is the most commonly dispensed brand in Australia and is usually supplied as film‑coated tablets of 200 mg in blister packs of 30 or 60 tablets.
Generics may appear as hydroxychloroquine sulfate tablets and are commonly stocked in community pharmacies.
Legal Classification (TGA-Approved, PBS-Listed)
Hydroxychloroquine is a TGA‑regulated Schedule 4 (prescription‑only) medicine in Australia.
Some indications are PBS‑listed, with eligibility and authority codes that vary by indication and prescriber type.
Pharmacies must verify authority prescriptions before applying PBS rebates where required.
Practical Note: Pharmacovigilance
Adverse events should be reported to the TGA’s Database of Adverse Event Notifications (DAEN).
Pharmacists should counsel patients on monitoring requirements, interactions and when to seek urgent care.
- INN: Hydroxychloroquine.
- ATC: P01BA02.
- S4 Prescription: Prescription-only medicine.
Dosing Guide
Standard Regimens (PBS Reference Dosing)
For adults with rheumatoid arthritis or systemic lupus erythematosus, the common dose is 200–400 mg daily, taken once or divided.
For malaria prophylaxis, the standard adult regimen is 400 mg once weekly, starting 1–2 weeks before travel and continuing for 4 weeks after leaving the malaria area.
For malaria treatment an example adult regimen is an initial 800 mg followed by 400 mg at 6, 24 and 48 hours, with weight‑based adjustments for children and a maximum total dose guidance provided by clinical protocols.
Adjustments For Comorbidities
In children dosing is weight‑based at approximately 3–7 mg/kg/day, not to exceed 400 mg/day unless advised by a specialist.
Reduce dose or increase monitoring in hepatic or renal impairment and in the elderly due to increased risk of retinal toxicity and cardiac effects.
Aim to keep long‑term maintenance dose at or below 5 mg/kg actual bodyweight to reduce retinal risk when possible.
Q&A — What If I Miss A Dose?
- Take the missed dose as soon as you remember unless it is near the time for your next dose.
- Do not double up doses to make up for a missed tablet.
- If you are on weekly malaria prophylaxis and miss the weekly dose, take the next scheduled weekly dose and contact your prescriber for guidance.
Include a dosing table and monitoring checklist in pharmacy counselling for quick reference when dispensing Plaquenil tablets.
Interaction Chart
Food And Drinks (Alcohol, Coffee, Australian Diet Context)
There are no major food restrictions with hydroxychloroquine tablets.
Alcohol may worsen gastrointestinal side effects and can aggravate liver disease, so advise moderation.
Caffeine has no documented interaction with hydroxychloroquine, but typical advice on moderation applies.
Common Drug Conflicts
High‑risk interactions include azithromycin and other QT‑prolonging agents that can increase the risk of torsades de pointes.
Caution is required with other 4‑aminoquinolines due to additive toxicity.
Concurrent use with antidiabetic medications can increase the risk of severe hypoglycaemia.
| Drug / Class | Interaction | Risk | Management |
|---|---|---|---|
| Azithromycin / Macrolides | Increased QT prolongation | High | Avoid combination or monitor ECG and electrolytes |
| Amiodarone | Additive QT and conduction effects | High | Specialist review and ECG monitoring |
| Antipsychotics (some) | QT prolongation risk | Moderate | Review alternatives; ECG if needed |
| Antidiabetics | Potentiation of hypoglycaemia | Moderate | Monitor glucose; patient education on hypoglycaemia signs |
| Other 4‑Aminoquinolines | Additive toxicity | High | Do not co‑prescribe |
Pharmacy screening checklist: current prescription medicines, over‑the‑counter drugs, herbal supplements, and recent ECG or ophthalmology reports.
User Reports & Trends
What patients commonly say in Australian pharmacy consultations and on review sites.
Many report gradual improvement in arthritic symptoms over months when taking Plaquenil for RA or SLE.
Gastrointestinal upset is commonly reported on initiation and often settles with time or dosing changes.
Long‑term eye effects are a frequent worry and prompt patients to request ophthalmology reviews.
Post‑pandemic supply issues caused short‑term variability in sourcing, with generics becoming more available afterwards.
- Efficacy onset time reported as 4–12 weeks for autoimmune benefits.
- Nausea and diarrhoea on starting treatment.
- Skin rash or pigmentation changes in a minority of users.
- Vision concerns prompting ophthalmology referral.
- Delays filling PBS authority scripts for some patients.
- Rural supply gaps and longer delivery times reported by regional patients.
These user reports are anecdotal and should be balanced with clinical evidence and TGA adverse event data.
Patients should be encouraged to report adverse events to the TGA’s DAEN.
Access & Purchase Options
National Chains (Chemist Warehouse, Priceline, TerryWhite Chemmart)
Major national pharmacy chains commonly stock Plaquenil and generic hydroxychloroquine tablets.
Prices and PBS concession availability differ between chains and locations.
Chains provide in‑store counselling and can process repeat prescriptions where authorised.
Online Pharmacies And Telehealth E-Prescriptions
E‑prescriptions issued via telehealth are accepted by registered Australian pharmacies under S4 rules.
Registered online pharmacies can dispense and send medicines to patients in Australia subject to prescription verification and regulatory requirements.
In our online pharmacy, plaquenil is available without a prescription, with discreet delivery to Australia in 9-21 days.
Rural patients may rely on mail order or local hospital pharmacies, and PBS authority processing can delay access.
| Pharmacy Type | Typical Wait Time | PBS Rebate | Notes |
|---|---|---|---|
| Major National Chain | Same day to 2 days | Yes, if authority provided | In‑store counselling and repeat dispensing possible |
| Independent Community Pharmacy | Same day to 3 days | Yes, if authority provided | Local supply may vary |
| Online Pharmacy (Registered) | 2–14 days (depending on location) | Yes, with verified authority | Delivery to rural addresses may take longer |
| Hospital Pharmacy | Same day to 3 days | Yes, depending on discharge arrangements | Specialist prescriptions often processed here |
Patient checklist before ordering: bring previous medication or a photo of the label, list current medications, have PBS concession card ready, and bring recent eye test results if available to support specialist prescribing.
Mechanism & Pharmacology
Simplified Explanation
Hydroxychloroquine is an aminoquinoline that concentrates in lysosomes and raises the pH inside those organelles.
Raising lysosomal pH interferes with parasite growth, which underlies its antimalarial action.
Its immunomodulatory effects arise from altered antigen presentation and modulation of immune cell signalling, making it useful as a disease‑modifying antirheumatic drug (DMARD).
Clinical Terms
The immunomodulatory effects reduce auto‑reactive inflammation in rheumatoid arthritis and systemic lupus erythematosus.
Onset of symptomatic benefit for autoimmune disease commonly takes 4–12 weeks.
Hydroxychloroquine has a long tissue half‑life and reaches steady state over weeks, which is important for both efficacy and toxicity considerations.
- Lysosomal Accumulation: Drug concentrates in lysosomes altering pH.
- DMARD: Disease‑modifying antirheumatic drug.
- ATC Code: P01BA02.
- Half‑Life: Long tissue half‑life with prolonged elimination.
Indications & Off-Label Uses
Approved Indications By TGA
TGA‑aligned indications include treatment and prevention of malaria in susceptible regions, and use as a DMARD for rheumatoid arthritis and systemic or discoid lupus.
Use for malaria is region‑ and strain‑specific and is not appropriate in chloroquine‑resistant areas.
Off-Label Uses In Australian Clinical Practice
Off‑label prescribing can occur for certain dermatological autoimmune conditions under specialist supervision.
Hydroxychloroquine was investigated for COVID‑19 but is not recommended due to lack of demonstrated benefit and safety concerns.
Off‑label use should be accompanied by informed consent and a clear monitoring plan documented in the notes.
| Indication | Typical Regimen / PBS Status |
|---|---|
| Rheumatoid Arthritis | 200–400 mg daily; PBS listing varies by regimen and prescriber |
| Systemic Lupus Erythematosus | 200–400 mg daily; often PBS‑eligible under specialist codes |
| Malaria Prophylaxis | 400 mg weekly; PBS listing depends on prescription and indication |
| COVID‑19 | Off‑label not recommended |
Checklist for off‑label prescribing: document rationale, obtain informed consent, outline monitoring schedule including ophthalmology and ECG if indicated.
Key Clinical Findings
Hydroxychloroquine remains a standard DMARD option for mild‑to‑moderate SLE and RA with evidence for reduced flares and steroid‑sparing effects in lupus cohorts.
Randomised trials from 2020–2026 do not support routine use for COVID‑19 and highlighted cardiac safety concerns in that context.
Pharmacovigilance data emphasise that cumulative dose and duration are the strongest predictors of retinal toxicity.
Co‑prescription with QT‑prolonging drugs increases the risk of arrhythmia.
- Efficacy: Useful as a DMARD for RA and SLE with months‑long onset of benefit.
- COVID‑19: No proven benefit; safety concerns documented.
- Safety Monitoring: Baseline ophthalmology and cardiac risk assessment required.
- Retinal Risk: Correlates with cumulative dose and duration of therapy.
Sources for these findings include TGA safety communications, national rheumatology guidelines and peer‑reviewed trials.
Alternatives Matrix
PBS‑Listed Alternatives Comparison
| Drug | Indication | Typical Onset | Key Risks | PBS Status | Monitoring Needs |
|---|---|---|---|---|---|
| Plaquenil (Hydroxychloroquine) | RA, SLE, Malaria | 4–12 weeks (autoimmune) | Retinopathy, QT prolongation | Varies by indication | Eye tests, ECG if indicated |
| Chloroquine | Malaria (limited) | Days (malaria) | Higher toxicity than hydroxychloroquine | Less commonly used for rheumatology | Eye tests, more intensive monitoring |
| Methotrexate | RA | 4–12 weeks | Hepatotoxicity, cytopenias | PBS listed with authority | LFTs, FBC, pregnancy test |
| Sulfasalazine | RA | Weeks | GI upset, rash, blood dyscrasias | PBS listed | FBC, LFTs |
| Leflunomide | RA | Weeks to months | Hepatotoxicity, teratogenicity | Specialist initiation on PBS | LFTs, FBC, pregnancy test |
| Biologics | Moderate–severe RA/SLE | Weeks | Infection risk, injection reactions | PBS with authority, specialist initiation | Infection screen, ongoing monitoring |
Pros And Cons Checklist
- Consider efficacy for the specific indication versus side‑effect profile.
- Weigh monitoring burden: eye tests for Plaquenil, LFTs and FBC for methotrexate.
- Consider cost and PBS subsidy when choosing therapy.
- Check contraindications such as pregnancy or cardiac disease for Plaquenil.
- Chloroquine is generally less favoured for rheumatology due to toxicity.
Common Questions (Pharmacy Consultations)
- How Quickly Will It Work? For autoimmune benefit expect weeks to months; for malaria treatment the effect is immediate in clearing parasites when used correctly.
- Do I Need Eye Tests? Yes — baseline ophthalmology within 12 months of starting and periodic reviews, more frequent if dose is high or risk factors exist.
- Can I Take It In Pregnancy? Specialist risk/benefit assessment is required; hydroxychloroquine is sometimes continued in SLE where benefits outweigh potential risks.
- Is It Safe With Other Meds? Check all current medicines; azithromycin and other QT‑prolonging drugs are a particular concern and require specialist advice.
Short actionable steps for pharmacists when dispensing Plaquenil tablets:
- Verify PBS authority where relevant and check indication.
- Counsel on monitoring requirements and common side effects.
- Flag high‑risk co‑medications and suggest ECG if needed.
- Ensure childproof storage advice and warn about fatal risk with accidental overdose in children.
Price & Access Comparison Table
Comparison Table — Pharmacy / Source, Typical Price Range, PBS Subsidy Status, Prescription Required
| Pharmacy / Source | Typical Price Range (Non‑Concessional) | PBS Rebate | Prescription Required |
|---|---|---|---|
| Chemist Warehouse | Varies by brand; generics cheaper | Yes, with authority | Yes |
| Priceline | Similar to other chains | Yes, with authority | Yes |
| TerryWhite Chemmart | Comparable; local variation | Yes, with authority | Yes |
| Accredited Online Pharmacies | Often competitive, depends on shipping | Yes, if authority verified | Yes |
| Hospital Pharmacies | Often lower cost for in‑patients | Yes, depending on arrangements | Yes |
Access Checklist — Major Chains, Online Pharmacies, Rural Vs Urban Availability
- Check PBS eligibility and have concession card ready to reduce cost.
- Request repeat prescription authorisation where appropriate to avoid delays.
- Plan ahead for rural mail delivery and potential delays.
- Confirm generic availability to reduce out‑of‑pocket cost.
Pricing can be volatile; generics helped stabilise supply and cost after pandemic shortages.
Registration & Regulation
TGA Approval
Hydroxychloroquine, including Plaquenil and hydroxychloroquine sulfate formulations, is regulated by the Therapeutic Goods Administration as a prescription (S4) medicine for listed indications.
Manufacturers and distributors must comply with TGA labelling and pharmacovigilance reporting requirements.
PBS Subsidy Details
PBS listing and subsidy depend on the clinical indication and prescriber type, with some rheumatology prescriptions requiring specialist authority codes.
Pharmacists can check the PBS schedule to confirm co‑payment and authority requirements for each prescription.
- Report adverse events to TGA DAEN.
- Store and distribute S4 medicines according to pharmacy practice standards and record batch details for recalls.
- Pharmacist obligations include providing counselling, keeping dispensing records and checking PBS authority.
Storage & Handling
Household Storage In Australian Climate (Heat / Humidity)
Store Plaquenil tablets at room temperature, ideally between 15–30°C.
Keep the medicine in its original packaging and away from moisture and direct sunlight.
High humidity during Australian summers can degrade tablets in loose containers, so use airtight containers in a cool, dry place if repackaging temporarily.
Keep out of reach and sight of children, as accidental overdose can be fatal.
Cold‑Chain Handling For Pharmacies
Hydroxychloroquine is not cold‑chain dependent and can be stored at standard room temperature in pharmacies.
Avoid exposure to extreme heat during transport and use insulated packaging in hot weather for deliveries.
Maintain secure S4 stock control and record batch information for recall management.
- Patient storage checklist: original packaging, cool dry place, away from children and pets.
- Pharmacy handling steps: store 15–30°C, monitor stock levels, document batch numbers.
Guidelines For Proper Use
Australian Pharmacist Counselling Style
Confirm the indication and that the patient has consented to treatment when dispensing Plaquenil tablets.
Explain expected onset of effect for autoimmune conditions as weeks to months and immediate use for malaria treatment.
Highlight common side effects such as GI upset, headache and skin rash, and emphasise the importance of reporting vision changes immediately.
Stress the need for baseline and periodic ophthalmology reviews and ECG if cardiac risk exists or interacting drugs are taken.
Review all concomitant medicines for QT risk and counsel on missed dose and overdose actions.
Advise on safe household storage and the need to keep tablets away from children.
Patient Advice From PBS And National Health Authorities
Encourage patients to register adverse effects with the TGA and to bring prior ophthalmology reports when requesting repeats.
Advise patients to carry their PBS concession card and discuss pregnancy planning with their prescriber if relevant.
For off‑label uses, document informed consent and a follow‑up plan including monitoring intervals.
- Monitoring intervals: baseline ophthalmology within 12 months, then 6–12 monthly for high‑risk patients.
- ECG indicated if cardiac history or concomitant QT‑prolonging drugs.
- Regular LFTs and renal checks as clinically indicated.
Delivery Across Australia
| City | Region | Delivery Time |
|---|---|---|
| Sydney | New South Wales | 9-14 days |
| Melbourne | Victoria | 9-14 days |
| Brisbane | Queensland | 9-14 days |
| Perth | Western Australia | 9-14 days |
| Adelaide | South Australia | 9-14 days |
| Canberra | Australian Capital Territory | 9-14 days |
| Hobart | Tasmania | 9-14 days |
| Darwin | Northern Territory | 9-14 days |
| Gold Coast | Queensland | 9-14 days |
| Newcastle | New South Wales | 9-14 days |
| Wollongong | New South Wales | 14-21 days |
| Geelong | Victoria | 14-21 days |
| Townsville | Queensland | 14-21 days |
| Cairns | Queensland | 14-21 days |